PAPPA and coronary artery disorder: Currently available biomarkers, such as high-sensitivity C-reactive protein (hsCRP), interleukin-6, myeloperoxidase (MPO), pregnancy-associated plasma protein-A (PAPP-A), myeloperoxidase, leukocyte counts, are inadequate for the diagnosis of CHD due to their poor clinical practice (Danesh et al., 2004; Lobbes et al., 2010; Wang et al., 2017; Li et al., 2018).